A Single-arm, Non-blind, Single-center Study to Evaluate the Safety and Tolerability of Rituximab Down-regulating Immunoglobulin (Ig) Treatment in Children With Duchenne Muscular Dystrophy (DMD) Who Can Walk
Latest Information Update: 19 Mar 2026
At a glance
- Drugs Rituximab (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
Most Recent Events
- 19 Mar 2026 New trial record